Rhogam and AIDS
FDA and CDC have concluded that Ortho's plasma product for RH disease did not cause a woman, who had tested positive for AIDS, to become infected with the virus ("The Pink Sheet" Oct. 12 "In Brief"). The agencies determined that "the alcohol fractionation method used in preparing Rhogam would inactivate any virus that might be present and there are other, more likely sources of the AIDS virus for this woman." FDA and CDC recommend that facilities awaiting results of the investigation resume using Rhogam.
You may also be interested in...
Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.